Skip to content
lifestyle.washingtonguardian.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Palvella Therapeutics Inc.
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
March 31, 2026
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
March 30, 2026
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
March 27, 2026
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
March 24, 2026
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
March 23, 2026
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
March 16, 2026
Palvella Therapeutics Launches “BEYOND mLM” Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
March 10, 2026
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
March 2, 2026
Palvella Therapeutics Announces Pricing of Upsized Public Offering
February 25, 2026
Palvella Therapeutics Announces Proposed Public Offering
February 24, 2026
←
Previous Page
1
2
3
Next Page
→